ERBB2 and breast cancer: It is also approved for HER2+ Early BC (HER2+ EBC) as adjunctive therapy after surgery, chemotherapy, or radiotherapy in combination with paclitaxel or docetaxel, in combination with docetaxel and carboplatin, or in combination with adjuvant chemotherapy followed by adjuvant monotherapy.